PMC:7408073 / 16-357
Annnotations
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 52-76 | Body_part | denotes | Renin-Angiotensin System | http://purl.obolibrary.org/obo/UBERON_0018229 |
| T2 | 177-201 | Body_part | denotes | renin-angiotensin system | http://purl.obolibrary.org/obo/UBERON_0018229 |
| T3 | 203-206 | Body_part | denotes | RAS | http://purl.obolibrary.org/obo/UBERON_0018229 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 4 | 4-7 | Gene | denotes | ACE | Gene:59272 |
| 5 | 8-12 | Gene | denotes | ACE2 | Gene:59272 |
| 6 | 52-57 | Gene | denotes | Renin | Gene:5972 |
| 7 | 91-99 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 25 | 240-248 | Species | denotes | patients | Tax:9606 |
| 26 | 261-271 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 31 | 249-257 | Disease | denotes | infected | MESH:D007239 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 91-99 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T2 | 261-269 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T3 | 261-265 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 58-69 | Chemical | denotes | Angiotensin | http://purl.obolibrary.org/obo/CHEBI_2719 |
| T2 | 183-194 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
| T3 | 203-206 | Chemical | denotes | RAS | http://purl.obolibrary.org/obo/CHEBI_63620 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T2 | 23-108 | Sentence | denotes | The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients |
| T3 | 110-118 | Sentence | denotes | Abstract |
| T4 | 119-326 | Sentence | denotes | The article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. |